News Releases

<< Back
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007

Annual Revenues Increase 147% In First Full-Year Of Profitability

CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, today reported revenues of $18.6 million for the fourth quarter ended December 31, 2007, an increase of 137% over revenues of $7.8 million for the comparable period in 2006. For the full year ended December 31, 2007, the Company reported revenues of $59.3 million, an increase of 147% over revenues of $24.0 million for the same period in 2006.

"We are proud of our accomplishments in 2007, moving first to profitability then to the public markets, all while growing our core business and building a solid infrastructure for continued expansion," said Tina Nova Bennett, Ph.D., President and CEO of Genoptix.

Fourth Quarter 2007

Gross profit for the fourth quarter of 2007 improved to $11.0 million, or 59% of revenues, from $4.0 million, or 51% of revenues, for the fourth quarter of 2006, a 175% improvement year-over-year resulting from an increase in sales and the leverage gained from additional case volumes.

Operating expenses for the fourth quarter of 2007 increased to $6.9 million from $4.3 million in the fourth quarter of 2006. These expenses were driven by investment in rapid organizational growth and ultimately contributed to operating income of $4.1 million in the fourth quarter of 2007, or 22% of revenues, as compared to a loss of $304 thousand during the same period in 2006.

GAAP net income for the fourth quarter of 2007 was $4.7 million, or diluted earnings per share (EPS) of $0.27, compared to a net loss of $358 thousand, or a net loss of $2.40 per diluted share, for the comparable period in 2006.

Full Year 2007

Gross profit for the full-year 2007 reached $35.2 million, pushing gross margins to 59%, up from $10.9 million, or 45% of revenues, for all of 2006. This improvement was primarily due to increases in case volume and service revenues resulting from an expanded sales effort and a net increase in Medicare reimbursement rates.

Operating expenses for 2007 increased to $22.2 million from $14.8 million for the full-year 2006, decreasing as a percentage of revenues to 37% for 2007, compared to 62% for all of 2006. Increased expenses were driven by the cost of additional personnel hired to support continued growth and infrastructure expansion. Operating income improved on a year-over-year basis, growing to just over $13 million at the end of 2007 from a loss of $3.9 million in 2006.

For the year, GAAP net income in 2007 increased to $13.4 million, $3.3 million of which is allocable to common shareholders, resulting in EPS of $0.78 on 4.2 million shares of weighted average common stock outstanding during the period. This compares to a net loss of $3.8 million, or a net loss of $33.74 per diluted share, for the full year 2006.

As of December 31, 2007, the Company's cash and cash equivalents and investment securities available-for-sale totaled $85.5 million compared to $3.9 million in the same period one year ago. Following completion of its IPO in November 2007, the Company received net proceeds of $72.5 million (after underwriting discounts, commissions and offering costs). For the full year ended December 31, 2007, cash generated from operations was $13.1 million, while purchases of capital equipment for the same period totaled $1.2 million.

"Once again, we improved our performance metrics over prior periods, ending the year with DSOs lowered to 52 days and further reducing bad debt expense to approximately 2% of our total revenues," said Sam Riccitelli, Genoptix EVP and COO. "Our solid operational execution and resulting cash flows support our reinvestment in future growth as we seek to enhance operational performance and provide added value to our core customers."

2008 Performance Outlook

For the full-year 2008, Genoptix expects revenues of approximately $90 million, resulting from expanded sales efforts and additional increases in case volumes.

The company also expects net income for 2008 of between $15 and $17 million (assuming an annual tax rate of 5% after utilizing our net operating loss carryforwards), which includes the impact of an estimated $6 million in non-cash stock-based compensation, an increase resulting primarily from expenses associated with the initiation of the Company's equity incentive programs. GAAP earnings per diluted share are expected to be in the range of $0.85 to $0.95 for the full year 2008.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company is projecting capital expenditures of between $4 million and $6 million for the full-year 2008.

Conference Call Information

A conference call will take place on Tuesday, February 12, 2008, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO Tina Nova Bennett, Ph.D., and other members of senior management. To access the live conference call via phone, dial 888-713-4214 in the U.S. or Canada and 617-213-4866 for international callers. The participant code for the call is 56532675. A replay of the call will be available through Friday, February 22, 2008. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 77232785.

The conference call will also be webcast live on the Internet and is accessible through the investor relations section of the Genoptix website at http://www.genoptix.com, or by accessing the external website, http://www.fulldisclosure.com. An online replay is planned to follow shortly after and will be available until Wednesday, March 12, 2008. To participate in the webcast, please connect to the Genoptix website several minutes prior to start time to register, download and install any necessary software that may be required.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the success of the Company's business model, the Company's ability to continue to expand its business and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects, DSOs, and the Company's financial guidance for 2008. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks and the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. Certain other risks and uncertainties are detailed in the annual report on Form 10-K for the full-year period ended December 31, 2007 that was filed with the United States Securities and Exchange Commission on February 12, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Genoptix undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

                          [Financial tables follow]



                                GENOPTIX, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                                (in thousands)

                                                          December 31,
                                                    2007              2006

    Assets
    Current assets:
      Cash and cash equivalents                    $50,624            $3,865
      Investment securities available-for-sale      34,836                 -
      Accounts receivable, net of allowance for
       doubtful accounts                             9,013             4,766
      Other current assets                           1,409               270
    Total current assets                            95,882             8,901
    Property and equipment, net                      1,950             1,287
    Other long-term assets                               -                14
    Total assets                                   $97,832           $10,202

    Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable and accrued expenses         $4,312            $1,987
      Accrued compensation                           2,496             1,058
      Deferred revenue                                  95                39
      Current portion of long-term debt                  -             1,524
    Total current liabilities                        6,903             4,608
    Deferred rent                                      324               267
    Long-term debt, net of current portion               -             1,262

    Commitments and contingencies

    Stockholders' equity :
      Preferred stock                                    -                52
      Common stock                                      16                 -
      Additional paid-in capital                   132,532            59,362
      Accumulated other comprehensive income            53                 -
      Accumulated deficit                          (41,996)          (55,349)
    Total stockholders' equity                      90,605             4,065
    Total liabilities and stockholders' equity     $97,832           $10,202



                                GENOPTIX, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                    (in thousands, except per share data)

                                          Three Months Ended    Years Ended
                                              December 31,      December 31,
                                             2007      2006    2007     2006
                                         (unaudited)(unaudited)

    Revenues                                $18,562  $7,828  $59,332  $24,018
    Cost of revenues                          7,563   3,823   24,106   13,131
    Gross profit                             10,999   4,005   35,226   10,887
    Operating expenses:
      Sales and marketing expenses            3,780   2,127   11,649    6,264
      General and administrative expenses     2,979   1,962    9,976    6,930
      Research and development expenses          96     220      559    1,080
      Impairment and lease exit costs             -       -        -      542
    Total operating expenses                  6,855   4,309   22,184   14,816
    Income (loss) from operations             4,144    (304)  13,042   (3,929)
      Interest income                           817      53    1,062      246
      Interest expense                         (122)    (96)    (353)    (384)
      Other income                                -     (11)      41      308
    Income (loss) before income taxes         4,839    (358)  13,792   (3,759)
    Provision for income taxes                 (165)      -     (439)       -
    Net income (loss)                        $4,674   $(358) $13,353  $(3,759)

    Net income (loss) per share(1)(2):
      Basic                                   $0.30  $(2.40)   $1.20  $(33.74)
      Diluted                                 $0.27  $(2.40)   $0.78  $(33.74)
    Shares used to compute net income
     (loss) per share:
      Basic                                  10,367     149    2,756      111
      Diluted                                11,909     149    4,246      111

    (1) As a result of the conversion of the Company's preferred stock into
        11,032 shares of common stock upon completion of the Company's IPO in
        November 2007, there is a lack of comparability in the basic and
        diluted net income (loss) per share amounts for the periods presented
        above. See Note 1 to the Notes to Consolidated Financial Statements in
        the Annual Report on Form 10-K for the year ended December 31, 2007
        for calculations of the pro forma net income (loss) per share for the
        periods presented.

    (2) For the three months ended December 31, 2007, $1,514 of the Company's
        net income of $4,674 was allocated to preferred stockholders for
        purposes of calculating net income per share pursuant to the terms of
        the preferred stock, resulting in $3,160 of net income allocable to
        common stockholders.  For the year ended December 31, 2007, $10,036 of
        the Company's net income of $13,353 was allocated to preferred
        stockholders for purposes of calculating net income per share pursuant
        to the terms of the preferred stock, resulting in $3,317 of net income
        allocable to common stockholders.  See Note 1 to the Notes to
        Consolidated Financial Statements in the Annual Report on Form 10-K
        for calculations of the pro forma net income (loss) per share for the
        periods presented.

SOURCE Genoptix, Inc.

CONTACT: Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc., +1-760-930-7150, investorrelations@genoptix.com; or Joleen Schultz, Principal of Mentus, +1-858-455-5500, ext 215, jschultz@mentus.com, for Genoptix, Inc.
Web site: http://www.genoptix.com
http://www.prnewswire.com